AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

NCT02511795 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Solid Tumours
Relapsed Small Cell Lung Cancer (SCLC)

Interventions

DRUG: AZD1775
DRUG: Olaparib

Sponsor

AstraZeneca